查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957729

2026年全球放射性配體療法市場報告

Radioligand Therapy Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，放射性配體療法的市場規模迅速擴張。預計該市場規模將從2025年的66.3億美元成長到2026年的73.2億美元，複合年成長率（CAGR）為10.4%。成長要素包括放射性配體供應受限、對傳統癌症療法的依賴、人們對標靶治療益處的認知不斷提高、醫院對核醫學技術的應用日益廣泛，以及早期放射性配體療法藥物獲得監管部門核准。

預計未來幾年放射性配體治療市場將快速成長，到2030年將達到107.2億美元，複合年成長率（CAGR）為10.0%。預測期內的成長要素包括新型α和BETA發射裝置的研發進展、聯合釋放療法的推廣、與精準腫瘤學的融合、神經系統和心血管領域臨床試驗的增加，以及對居家醫療和門診放射性配體治療服務投資的增加。預測期內的關鍵趨勢包括標靶放射性配體治療在腫瘤學領域的應用日益廣泛、基於α和BETA發射裝置的治療方法不斷擴展、放射性配體治療與個體化醫療方法的融合、醫院和研究機構開展的放射性配體治療項目的成長，以及減少副作用和改善患者預後的重要性日益凸顯。

癌症發生率的急劇上升預計將推動放射性配體療法市場的發展。癌症是一種不受控制的異常細胞增生侵襲並轉移至周圍組織的疾病。癌症發生率的上升與長期暴露於環境毒素密切相關，這些毒素會誘導DNA損傷、細胞功能障礙和異常增殖。放射性配體療法透過受體結合配體誘導輻射，並精確照射腫瘤，抑制癌症，從內部殺死癌細胞，同時保護健康組織。例如，截至2025年10月，英國國家醫療服務體系（NHS）記錄了2023年新增癌症病例354,820例（平均每天972例），比2022年增加了8,605例。因此，癌症發生率的上升正在推動放射性配體療法市場的成長。

放射性配體治療市場的主要企業正在開發專門的設施，以最佳化精準癌症療法的生產和供應，提高效率、品質和安全性。放射性配體治療設施是專門用於癌症治療的放射性藥物管理中心，配備了最先進的影像設備、屏蔽系統、專家團隊和嚴格的安全措施。例如，2024年1月，瑞士製藥巨頭諾華公司在獲得美國食品藥物管理局（FDA）的商業核准後，對其位於印第安納州的大規模放射性配體治療（RLT）工廠進行了自動化改造。這座佔地7萬平方英尺的工廠是諾華公司規模最大、技術最先進的RLT生產基地，透過全自動化實現了快速、大規模的生產，並擴大了對美國和加拿大患者的供應。

目錄

第1章：執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球放射性配體治療市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物聯網、智慧基礎設施、互聯生態系統
  • 主要趨勢
    • 標靶放射性配體療法在腫瘤學的應用拓展
    • 基於α射線和BETA射線發射體的治療方法的擴展
    • 放射性配體療法與個人化醫療方法的整合
    • 醫院和研究機構的放射性配體治療項目增加
    • 人們越來越關注如何最大限度地減少副作用並改善患者預後。

第5章 終端用戶產業市場分析

  • 醫院
  • 診斷檢查室
  • 研究機構
  • 居家醫療環境
  • 專科癌症中心

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球放射性配體治療市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球放射性配體治療市場規模、對比及成長率分析
  • 全球放射性配體療法市場表現：規模與成長，2020-2025年
  • 全球放射性配體療法市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按放射性配體類型
  • α粒子發射裝置、BETA粒子發射裝置、俄歇粒子發射裝置、複合發射裝置
  • 按分子標靶分類
  • 荷爾蒙受體、生長因子受體、抗原腫瘤標記和其他分子標靶
  • 透過行政途徑
  • 靜脈注射（IV）、肌肉注射（IM）、皮下注射、口服
  • 透過使用
  • 腫瘤科、心血管疾病科、神經系統疾病科、感染疾病
  • 最終用戶
  • 醫院、診斷檢查室、研究機構、居家醫療環境
  • 按類型細分：α粒子發射材料
  • 錒-225 (Ac-225)、鐳-223 (Ra-223)、砹-211 (At-211)、鉍-213 (Bi-213)
  • 依型別細分：BETA射線發射體
  • 鎦-177 (Lu-177)、碘-131 (I-131)、釔-90 (Y-90)、釤-153 (Sm-153)
  • 按類型細分：螺旋式發射器
  • 碘-125 (I-125)、銦-111 (In-111)、鎵-67 (Ga-67)、鉈-201 (Tl-201)
  • 按類型細分：綜合排放
  • 鋱-161 (Tb-161)、銅-67 (Cu-67)、錸-186 (Re-186)、鉛-212 (Pb-212)

第10章 區域與國別分析

  • 全球放射性配體治療市場：按地區分類，實際結果和預測，2020-2025年、2025-2030年、2035年
  • 全球放射性配體治療市場：按國家/地區分類，實際結果和預測，2020-2025 年、2025-2030 年、2035 年

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 放射性配體療法市場：競爭格局與市場佔有率，2024 年
  • 放射性配體療法市場：公司估值矩陣
  • 放射性配體療法市場：公司概況
    • Novartis AG
    • Lantheus Holdings Inc.
    • Curium LLC
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Telix Pharmaceuticals

第37章 其他大型企業和創新企業

  • Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年放射性配體治療市場：提供新機會的國家
  • 2030年放射性配體治療市場：充滿新機會的細分市場
  • 2030年放射性配體療法市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH4MRTHE03_G26Q1

Radioligand therapy (RLT) is an advanced targeted cancer treatment that combines a radioactive isotope with a ligand engineered to bind specifically to cancer cell receptors. Once administered, it locates tumor cells and delivers radiation directly to them, minimizing harm to healthy tissues. This targeted strategy helps reduce side effects and improve outcomes, especially in cancers resistant to conventional therapies.

The main types of radioligands in radioligand therapy include alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, typically just a few cell layers, making them highly effective for precise cell destruction. These radioligands target specific molecular markers such as hormone receptors, growth factor receptors, and tumor antigens, and can be administered via intravenous (IV), intramuscular (IM), subcutaneous, or oral routes. Radioligand therapy is applied in oncological, cardiovascular, neurological, and infectious disease treatments, and is utilized by hospitals, diagnostic laboratories, research institutions, and home care settings.

Tariffs have impacted the radioligand therapy market by increasing costs of imported radioactive isotopes, ligands, and specialized delivery equipment. Segments like alpha and beta emitter therapies are most affected, particularly in regions like North America and Europe, where imports dominate supply chains. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local production, investment in domestic radiopharmaceutical facilities, and innovation in cost-efficient RLT solutions.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including radioligand therapy industry global market size, regional shares, competitors with a radioligand therapy market share, detailed radioligand therapy market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

The upsurge in cancer incidence is anticipated to boost the radioligand therapy market ahead. Cancer involves runaway abnormal cell proliferation that infiltrates nearby areas and metastasizes. Its rise links to prolonged environmental toxin exposure harming DNA, impairing cells, and spurring rogue growth. Radioligand therapy combats cancer by channeling radiation via receptor-binding ligands to zap tumors precisely, sparing healthy tissue for internal cell kill. For example, in October 2025, the National Health Service (NHS), a UK public health body, recorded 354,820 new cases in 2023-972 daily, up 8,605 from 2022. Thus, the climbing cancer incidence is fueling the radioligand therapy market.

Prominent companies in the radioligand therapy market are advancing setups like specialized radioligand therapy facilities to optimize output, quality, and safety in crafting and supplying pinpoint cancer drugs. Radioligand therapy facilities are dedicated hubs managing radioactive agents for focused cancer care, equipped with cutting-edge imaging, shielding, expert staff, and rigorous safeguards. For instance, in January 2024, Novartis AG, a Switzerland pharma leader, automated its massive Indiana radioligand therapy (RLT) plant post-FDA commercial nod. Spanning 70,000 square feet, it's Novartis's biggest, most sophisticated RLT site for swift, high-volume runs with full automation, ramping supply for US and Canada patients.

In December 2023, Eli Lilly and Company, a US pharma giant, snapped up POINT Biopharma Global Inc. for $1.4 billion. This bolsters Eli Lilly's oncology range with top-tier radioligand tech for sharper cancer precision meds. POINT Biopharma Global Inc. is a US firm honing radioligand cancer therapies.

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
  • 2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
  • 3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
  • 4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
  • 5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
  • 2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
  • 3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
  • 4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
  • Companies Mentioned: Novartis AG; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Telix Pharmaceuticals; Mariana Oncology Inc.; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Radioligand Therapy Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Radioligand Therapy Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Radioligand Therapy Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Radioligand Therapy Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Targeted Radioligand Therapy For Oncology
    • 4.2.2 Expansion Of Alpha And Beta Emitter-Based Therapies
    • 4.2.3 Integration Of Radioligand Therapy With Personalized Medicine Approaches
    • 4.2.4 Growth In Hospital And Research Institution-Based RLT Programs
    • 4.2.5 Rising Focus On Minimizing Side Effects And Enhancing Patient Outcomes

5. Radioligand Therapy Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutions
  • 5.4 Home Care Settings
  • 5.5 Specialty Cancer Centers

6. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radioligand Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Radioligand Therapy Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Radioligand Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Radioligand Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radioligand Therapy Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radioligand Therapy Market Segmentation

  • 9.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
  • 9.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
  • 9.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
  • 9.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
  • 9.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
  • 9.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
  • 9.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
  • 9.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
  • 9.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

10. Radioligand Therapy Market Regional And Country Analysis

  • 10.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radioligand Therapy Market

  • 11.1. Asia-Pacific Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radioligand Therapy Market

  • 12.1. China Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radioligand Therapy Market

  • 13.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radioligand Therapy Market

  • 14.1. Japan Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radioligand Therapy Market

  • 15.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radioligand Therapy Market

  • 16.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radioligand Therapy Market

  • 17.1. South Korea Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radioligand Therapy Market

  • 18.1. Taiwan Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radioligand Therapy Market

  • 19.1. South East Asia Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radioligand Therapy Market

  • 20.1. Western Europe Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radioligand Therapy Market

  • 21.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radioligand Therapy Market

  • 22.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radioligand Therapy Market

  • 23.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radioligand Therapy Market

  • 24.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radioligand Therapy Market

  • 25.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radioligand Therapy Market

  • 26.1. Eastern Europe Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radioligand Therapy Market

  • 27.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radioligand Therapy Market

  • 28.1. North America Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radioligand Therapy Market

  • 29.1. USA Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radioligand Therapy Market

  • 30.1. Canada Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radioligand Therapy Market

  • 31.1. South America Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radioligand Therapy Market

  • 32.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radioligand Therapy Market

  • 33.1. Middle East Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radioligand Therapy Market

  • 34.1. Africa Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radioligand Therapy Market Regulatory and Investment Landscape

36. Radioligand Therapy Market Competitive Landscape And Company Profiles

  • 36.1. Radioligand Therapy Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Radioligand Therapy Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Radioligand Therapy Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Curium LLC Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Telix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Radioligand Therapy Market Other Major And Innovative Companies

  • Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

38. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radioligand Therapy Market

40. Radioligand Therapy Market High Potential Countries, Segments and Strategies

  • 40.1 Radioligand Therapy Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Radioligand Therapy Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Radioligand Therapy Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer